• 医学文献
  • 知识库
  • 评价分析
  • 全部
  • 中外期刊
  • 学位
  • 会议
  • 专利
  • 成果
  • 标准
  • 法规
  • 临床诊疗知识库
  • 中医药知识库
  • 机构
  • 作者
热搜词:
换一批
论文 期刊
取消
高级检索

检索历史 清除

医学文献 >>
  • 全部
  • 中外期刊
  • 学位
  • 会议
  • 专利
  • 成果
  • 标准
  • 法规
知识库 >>
  • 临床诊疗知识库
  • 中医药知识库
评价分析 >>
  • 机构
  • 作者
热搜词:
换一批

英夫利西单克隆抗体诱导和维持26例中重度克罗恩病患者深度缓解的疗效分析

Efficacy analysis of infliximab treatment in inducing and maintaining deep remission in 26 patients with moderate to severe Crohn's disease

摘要:

目的 探讨英夫利西单克隆抗体(IFX)对诱导和维持中重度CD患者深度缓解的疗效和安全性.方法 回顾性分析2012年2月至2014年4月接受IFX治疗的26例中重度CD患者的临床资料.观察治疗前,治疗后第14、30周时患者实验室指标(ESR、CRP、白蛋白)、克罗恩病活动度指数(CDAI)、克罗恩病简化内镜评分(SES-CD)、深度缓解率及不良反应的情况.正态分布计量资料的两组间比较采用t检验,非正态分布计量资料的两组间比较采用Wilcoxon符号秩检验,率的比较使用卡方检验或Fisher确切概率法.结果 26例CD患者中,与治疗前相比,治疗后第14周时患者CDAI评分明显下降[225.0(124.0,265.0)分比80.0(67.0,124.7)分,Z=-4.265,P<0.01]; ESR和CRP显著下降;BMI和白蛋白升高;临床缓解率为80.8%(21/26),内镜下黏膜愈合率为42.3%(11/26),深度缓解率为34.6%(9/26);病程<1年的患者有较高的临床缓解率(92.3%比69.2%,P=0.32).与治疗前相比,治疗后第30周时患者CDAI评分明显下降[225.0(124.0,265.0)分比81.5(67.0,111.0)分,Z=-4.877,P<0.01];ESR和CRP显著下降;BMI和白蛋白升高;临床缓解率为88.5%(23/26),内镜下黏膜愈合率为57.7%(15/26),深度缓解率为53.8%(14/26);病程<1年的患者有较高的临床缓解率(100.0%比76.9%,P=0.22).患者在治疗后第14、30周时临床缓解率、内镜下黏膜愈合率及深度缓解率方面的差异均无统计学意义(P均>0.05).结论 IFX可有效诱导和维持中重度CD患者的深度缓解.

更多
abstracts:

Objective To explore the efficacy and safety of infliximab (IFX) treatment in inducing and maintaining deep remission (DR) in patients with moderate to severe Crohn's disease (CD).Methods From February 2012 to April 2014,the clinical data of 26 patients with moderate to severe CD received IFX treatment were retrospectively analyzed.Laboratory indexes (erythrocyte sedimentation rate (ESR),C-reactive protein (CRP),albumin),Crohn's disease activity index (CDAI),Crohn's disease simplified endoscopic score (SES-CD),rate of DR and side effects were observed before treatment,at week 14 and week 30.The t test was performed for normal distribution measurement data comparison between two groups.Wilcoxon signed rank test was performed for non normal distribution measurement data comparison between two groups.Chi square test and Fisher exact probability method were used for rate comparison.Results In 26 patients with CD,at week 14,the CDAI significantly decreased compared with that before treatment (225.0(124.0,265.0) vs 80.0(67.0,124.7),Z=-4.265,P<0.01); ESR and CRP levels also significantly decreased while body mass index (BMI) and albumin levels increased.The rate of clinical remission,mucosal healing under endoscope and DR was 80.0 % (21/26),42.3 % (11/ 26) and 34.6% (9/26),respectively.The rate of clinical remission was higher in patients with the disease course less than one year (92.3% vs 69.2%,P=0.32).At week 30,the CDAI of patients significantly decreased compared with that before treatment (225.0(124.0,265.0) vs 81.5(67.0,111.0),Z=-4.877,P<0.01); the ESR and CRP levels significantly decreased; while the BMI and albumin levels increased.The rate of clinical remission,mucosal healing under endoscope and DR was 88.5 % (23/26),57.7%(15/26) and 53.8% (14/26),respectively.Rate of clinical remission was higher in patients with the disease course less than one year (100.0% vs 76.9%,P=0.22).The differences in the rates of clinical remission,mucosal healing and DR between week 14 and week 30 were not statistically significant.Conclusion IFX could induce and maintain DR in patients with moderate to severe CD.

More
  • 浏览:272
  • 下载:168

加载中!

相似文献

  • 中文期刊
  • 外文期刊
  • 学位论文
  • 会议论文

加载中!

加载中!

加载中!

加载中!

扩展文献

特别提示:本网站仅提供医学学术资源服务,不销售任何药品和器械,有关药品和器械的销售信息,请查阅其他网站。

  • 客服热线:4000-115-888 转3 (周一至周五:8:00至17:00)

  • |
  • 客服邮箱:yiyao@wanfangdata.com.cn

  • 违法和不良信息举报电话:4000-115-888,举报邮箱:problem@wanfangdata.com.cn,举报专区

官方微信
万方医学小程序
new翻译 充值 订阅 收藏 移动端

官方微信

万方医学小程序

使用
帮助
Alternate Text
调查问卷